# REGN7075

Source: https://onco.cc/drugs/regn7075/  
OnCo record `regn7075` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

REGN7075 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Regeneron Pharmaceuticals, in non-small-cell lung cancer, small-cell lung cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: EGFRxCD28 bispecific immunotherapy; marlotamig
- Tags: pipeline; ctgov-ingest; registry-only
- Code: REGN7075
- Modality: Bispecific antibody
- Mechanism: A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.

## Sources

- ClinicalTrials.gov: trials of REGN7075: https://clinicaltrials.gov/search?intr=REGN7075

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- trials: [A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce](https://onco.cc/trials/nct06465329/), [A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07154290/), [A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers](https://onco.cc/trials/nct04626635/)

---
JSON: https://onco.cc/api/v1/entities/regn7075.json